Suchergebnisse - "Elez, Elena"

PubPharm (174)

71

Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site : The METABEAM Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Kagawa, Y. | Elez, E. | García-Foncillas, J. | +17

72

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

enthalten in: Radiology | 2021

von Ligero, M. | Garcia-Ruiz, A. | Viaplana, C. | +28

CommentIn: Radiology. 2021 Jan 26;:204407. - PMID 33502277

73

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer : Updated Survival Results and Subgroup Analyses from the BEACON Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Tabernero, J. | Grothey, A. | Van Cutsem, E. | +16

CommentIn: J Clin Oncol. 2021 Feb 1;39(4):259-261. - PMID 33503394

74

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer

enthalten in: Therapeutic advances in medical oncology | 2021

von Ros, J. | Baraibar, I. | Sardo, E. | +8

75

The Effective Targeting of KRASG12C Elusiveness

enthalten in: Cancer cell | 2020

von Elez, E. | Tabernero, J.

CommentOn: N Engl J Med. 2020 Sep 24;383(13):1207-1217. - PMID 32955176

76

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

enthalten in: The New England journal of medicine | 2020

von André, T. | Shiu, K. | Kim, T. | +119

CommentIn: N Engl J Med. 2020 Dec 3;383(23):2283-2285. - PMID 33264550

77

A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K -mutant Solid Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Sullivan, R. | Weber, J. | Patel, S. | +10

78

AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Cardone, C. | Blauensteiner, B. | Moreno-Viedma, V. | +27

79

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR) : a phase 2, open-label, single-arm, multicentre basket trial

enthalten in: The Lancet. Oncology | 2020

von Subbiah, V. | Lassen, U. | Élez, E. | +16

CommentIn: Lancet Oncol. 2020 Nov;21(11):e515. - PMID 33152306

80

Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion

enthalten in: Clinical colorectal cancer | 2020

von Fernández-Montes, A. | Grávalos, C. | Pericay, C. | +7